The global theranostics market is anticipated to grow at a CAGR of 14.20% between 2025 and 2032, increasing from USD 2.31 billion in 2024 to USD 6.68 billion by 2032. This expansion is fueled by the rising prevalence of chronic diseases, particularly cancer, heightened investments, and the growing demand for targeted therapies. Advancements in diagnostics and therapeutics are enhancing treatment precision, while strong healthcare infrastructure and supportive policies are fostering innovation and accessibility in this rapidly evolving sector.
Increased funding, particularly in university hospitals, is accelerating market growth by facilitating the development of cutting-edge personalized medicine. These investments drive new diagnostic technologies, targeted therapeutic solutions, and translational research. Financial backing also promotes public-private collaborations, expedites regulatory approvals, and enhances access to theranostic solutions. For instance, in September 2024, the Theranostics Trial Center at Karolinska Institutet received a USD 1.4 million grant from Vinnova, Sweden’s innovation agency, to advance cancer treatment through image-guided diagnostics and radiolabeled targeted drugs, reinforcing market growth prospects.
The increasing need for personalized therapies is a key driver of the theranostics market, supported by the introduction of new theranostic products. In October 2024, Mediso Kft. launched the AnyScan TRIO SPECT/CT, TheraMAX at the EANM meeting, specifically designed for theranostic imaging. Its initial deployment at University Hospital Regensburg, Germany, enhances diagnostic accuracy akin to PET/CT, contributing to market expansion. The shift toward precision medicine is further encouraged by favorable regulatory frameworks and collaborations between pharmaceutical firms and research institutions, positioning theranostics as a cornerstone of personalized healthcare.
Click – https://www.marketsandata.com/industry-reports/theranostics-market
Government Initiatives and Investments Driving Demand
Government investments in cancer care programs are significantly boosting demand for theranostics. These initiatives are enhancing healthcare infrastructure, developing comprehensive cancer centers, and expanding access to high-tech diagnostic and treatment facilities, especially in lower-income regions. Developed nations are also increasing funding to improve cancer care.
For example, in January 2025, New York Governor Kathy Hochul allocated USD 188 million to seven hospitals under the Healthcare Safety Net Transformation Program. This includes developing a cancer care center at Jamaica Hospital and upgrading the emergency department at St. Barnabas Hospital. Additionally, India’s Rashtriya Arogya Nidhi program provides financial aid to economically disadvantaged cancer patients, enabling access to specialized treatment. Governments worldwide are integrating innovative solutions into national healthcare systems, promoting personalized medicine approaches such as theranostics, which are transforming global cancer management.
Regulatory Support Facilitating Market Expansion
The growing regulatory approval of theranostic agents is significantly driving market growth by increasing awareness and clinical adoption. Expedited approval processes, such as the FDA’s Breakthrough Therapy and Fast Track Designations, accelerate the entry of novel therapies into the market, encouraging R&D investments.
For instance, in July 2024, the FDA approved Radiopharm Theranostics Limited’s IND application for F18-Pivalate (RAD 101), an advanced imaging agent under clinical trials aimed at detecting and characterizing brain metastases. Streamlined regulatory pathways and supportive policies are enabling faster integration of innovative theranostic solutions into standard care, driving market expansion and reinforcing the push toward precision medicine.
Hospitals Leading the Market
Hospitals are expected to dominate the theranostics market due to their advanced infrastructure, high patient volumes, and widespread adoption of precision medicine. Multispecialty and tertiary care hospitals are leveraging theranostics for oncology, cardiology, and neurology treatments, enhancing diagnostic and therapeutic capabilities.
Partnerships between university hospitals and industry players are fostering research and clinical trials, advancing radiopharmaceuticals, biomarkers, and imaging technologies. For example, in June 2024, University Hospitals Cleveland and Siemens Healthineers extended their collaboration to improve oncology, cardiovascular, and neurovascular treatments in Ohio, with a focus on Alzheimer’s care and late-stage cancer therapies. Their partnership with Case Western Reserve University aims to develop new magnetic resonance technologies, accelerating theranostics adoption. These collaborations play a crucial role in advancing research, securing funding, and implementing innovative treatments.
North America Leading the Market
North America holds a significant share of the theranostics market, driven by its well-developed healthcare infrastructure, high cancer incidence, and extensive research activities. The region is home to major industry players leading innovations in radiopharmaceuticals, imaging agents, and targeted therapies. Rising cancer cases in the U.S. and Canada are fueling the demand for advanced diagnostic and treatment solutions.
Additionally, North America remains at the forefront of R&D, with numerous clinical trials focused on oncology, neurology, and cardiology. Both public and private sector investments are accelerating medical advancements, transforming treatment methodologies and improving patient outcomes.
For instance, in January 2025, First Ascent Biomedical Inc. secured a USD 6 million investment from Vidal Duart Enterprises, Inc., co-invested by Techstars, to further enhance personalized cancer treatment solutions. This funding underscores North America’s leadership in theranostics, highlighting the region’s role in shaping the global market. The growing awareness of personalized medicine in the region ensures a faster adoption of theranostic solutions, reinforcing its market dominance.
Future Market Outlook (2025-2032)
The growth of the theranostics market is driven by technological advancements integrating diagnostics and therapeutics for precision medicine. Innovations in nanotechnology, radiopharmaceuticals, and AI-driven imaging are revolutionizing disease treatment, particularly in oncology, cardiology, and neurology. Expanding investments in personalized medicine, increasing cancer prevalence, and strengthened academic-industry collaborations present significant growth opportunities. Additionally, improving healthcare infrastructure in developing regions is fostering the adoption of theranostics, enhancing patient outcomes.
Various initiatives are accelerating the adoption of theranostic solutions. In November 2024, Thera4Care launched an initiative to position Europe as a leader in theranostics by coordinating academic centers, healthcare professionals, SMEs, and industry stakeholders to improve radiotheranostics manufacturing and supply. This multidisciplinary collaboration is strengthening healthcare preparedness and unlocking substantial market growth potential.
Technological innovations are reshaping theranostics, driving market expansion. The integration of theranostics with AI is a transformative shift, enabling radiologists to analyze medical images with unparalleled precision. AI enhances diagnostics, streamlines treatment pathways, and facilitates personalized therapies, accelerating breakthroughs in cancer treatment and beyond. This technological convergence is optimizing workflows, improving patient care, and establishing theranostics as a cornerstone of future healthcare advancements.
Report Scope
The report “Theranostics Market Assessment, Opportunities, and Forecast, 2018-2032” by Markets and Data provides a detailed qualitative and quantitative analysis of the global theranostics market, industry trends, and key challenges. It includes market size projections, segmental shares, growth trends, opportunities, and forecasts for 2025-2032. Additionally, the report profiles leading industry players, detailing their market share, business models, and competitive positioning.
Latest reports-
https://www.marketsandata.com/industry-reports/agrivoltaics-market
https://www.marketsandata.com/industry-reports/acetic-acid-market
Contact
Mr. Vivek Gupta5741 Cleveland street,Suite 120, VA beach, VA, USA 23462Tel: +1 (757) 343–3258Email: info@marketsandata.comWebsite: https://www.marketsandata.com
“Global Streetcar Market 2024” Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2024 is Provided to Determine the Market Potential.
In this report, our team research the global Streetcar market by type, application,
Request a sample of Streetcar Market report @ http://www.arcognizance.com/enquiry-sample/445675
Geographically, global Streetcar market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
